Valuation: Amphastar Pharmaceuticals, Inc.

Market Cap 825M 722M 666M 615M 1.17B 78.72B 1.19B 7.96B 3.12B 38.78B 3.1B 3.03B 133B P/E 2026 *
14x
P/E 2027 * 10.6x
Enterprise Value 1.14B 994M 917M 847M 1.61B 108B 1.63B 10.95B 4.3B 53.38B 4.27B 4.17B 184B EV / Sales 2026 *
1.53x
EV / Sales 2027 * 1.28x
Free-Float
50.3%
Yield 2026 *
-
Yield 2027 * -
1 day-1.58%
1 week-4.68%
Current month-7.23%
1 month-7.74%
3 months-8.10%
6 months-32.52%
Current year-30.10%
1 week 18.52
Extreme 18.52
20.28
1 month 18.22
Extreme 18.22
22
Current year 16.64
Extreme 16.645
29.52
1 year 16.64
Extreme 16.645
31.26
3 years 16.64
Extreme 16.645
67.66
5 years 16.64
Extreme 16.645
67.66
10 years 12.05
Extreme 12.05
67.66
Manager TitleAgeSince
Chief Operating Officer 76 28/02/1996
Chief Executive Officer 79 28/02/1996
Director of Finance/CFO 58 31/03/2014
Director TitleAgeSince
Director/Board Member 69 31/01/2003
Director/Board Member 58 03/08/2022
Director/Board Member 66 31/05/2019
Date Insider Type Main position Quantity % Market Cap.
06-01Tax

Director

-769 0.0017%
05-31Free

Director

25,508 0.0579%
05-31Free

Director

25,508 0.0579%
Change 5-day change 1-year change 3-year change Capi.($)
-1.58%-4.68%-15.71%-67.12% 825M
-2.33%-2.09%+50.33%+162.29% 1,060B
-0.82%-2.30%+62.97%+61.11% 619B
-0.73%-4.98%+27.22%+84.46% 438B
+0.33%-1.17%+27.98%+26.90% 333B
-0.02%-2.85%+25.27%+44.88% 282B
-3.89%-11.22%+20.78%+26.07% 267B
+0.66%-1.42%-29.26%-39.30% 218B
-0.06%-2.88%+20.98%+61.70% 196B
-3.72%-1.10%+13.35%+71.53% 161B
Average -0.96%-3.24%+20.39%+43.25% 357.47B
Weighted average by Cap. -0.56%-2.96%+35.27%+81.24%

Financials

2026 *2027 *
Net sales 744M 651M 600M 554M 1.05B 70.96B 1.07B 7.17B 2.82B 34.96B 2.79B 2.73B 120B 778M 681M 628M 580M 1.1B 74.24B 1.12B 7.5B 2.95B 36.57B 2.92B 2.86B 126B
Net income 64M 55.98M 51.64M 47.69M 90.49M 6.1B 92.01M 617M 242M 3.01B 240M 235M 10.34B 84M 73.47M 67.77M 62.59M 119M 8.01B 121M 810M 318M 3.95B 315M 309M 13.57B
Net Debt 311M 272M 251M 232M 439M 29.64B 447M 3B 1.18B 14.6B 1.17B 1.14B 50.19B 173M 152M 140M 129M 245M 16.54B 249M 1.67B 656M 8.15B 651M 637M 28.01B
Logo Amphastar Pharmaceuticals, Inc.
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells active pharmaceutical ingredient (API) products. Most of the Company's finished products are contracted and distributed through group purchasing organizations, drug wholesalers, and drug retailers. The Company manufactures and sells over 25 prescription pharmaceutical products, and one over-the-counter product, Primatene MIST. Its marketed products include BAQSIMI (glucagon) nasal powder 3mg, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone, Cortrosyn, Amphadase, and Epinephrine injection. It manufactures and sells two API products: Recombinant Human Insulin (RHI API) and porcine insulin API. It is also focused on generic and proprietary product candidates in the injectable, inhalable, topical, and intranasal markets.
Employees
1,976
Date Price Change Volume
10/07/26 US$18.72 -1.58% 311,051
09/07/26 US$19.02 +0.74% 446,628
08/07/26 US$18.88 -5.98% 438,664
07/07/26 US$20.08 +2.40% 449,984
06/07/26 US$19.61 -0.15% 313,781
Trader
Investor
Global
Quality
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
7
Last Close Price
18.72USD
Average target price
22.00USD
Spread / Average Target
+17.52%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AMPH Stock